Every 10-Q that Drugs Made In America Acquisition II Corp. Unit (DMIIU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DMIIU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMIIU filings page.
Drugs Made In America Acquisition II Corp., a Cayman Islands blank check company, reports interim results as it seeks a pharmaceutical-focused business combination. It completed a $500,000,000 IPO in September 2025 and held $513,882,333 in a U.S. Treasury–invested Trust Account as of June 30, 2026, corresponding to 50,000,000 redeemable ordinary shares.
For the six months ended June 30, 2026, the company generated net income of $8,734,276, driven primarily by $8,948,533 of interest on Trust investments, while incurring $244,257 of general and administrative costs. Operating liquidity remains tight, with cash of $174,974, a working capital deficit of $426,751, and $17,500,000 of deferred underwriting fees plus $450,000 of convertible promissory notes outstanding. Management discloses substantial doubt about the company’s ability to continue as a going concern if no business combination occurs within the 24‑month combination period and also reports material weaknesses in internal controls, including inadequate segregation of duties and insufficient policies around related‑party approvals.
Drugs Made in America Acquisition II Corp. reported Q1 2026 net income of $4.34M, driven almost entirely by $4.44M of interest earned on $509.37M of cash and investments held in its SPAC trust account, while general and administrative costs were $132K.
Operating cash remains limited with $347,720 of cash and a working capital deficit of about $315K as of March 31, 2026, and management cites substantial doubt about its ability to continue as a going concern without completing a business combination within the 24‑month Combination Period. The company fully reserved $782,113 due from its sponsor and raised $450K via convertible notes that can convert at a 35% discount upon a future business combination.
Drugs Made In America Acquisition II Corp., a Cayman Islands-based blank check company, reports its first post-IPO quarter with $500,000,000 from the sale of 50,000,000 units at $10.00 per unit placed in a U.S. trust account, plus $12,000,000 from 1,200,000 private placement units. As of September 30, 2025, the trust account balance is $500,109,355, while cash outside the trust is $315,087 and working capital is $219,011.
For the nine months ended September 30, 2025, the company recorded a net loss of $143,558, driven by $252,913 of general and administrative costs, partially offset by $109,355 of interest income on trust investments. The SPAC has not yet identified a merger target but must complete a business combination within 24 months of the IPO closing or liquidate and return funds to public shareholders.
The filing highlights substantial doubt about the company’s ability to continue as a going concern due to the fixed liquidation date and limited cash outside the trust. Management also reports material weaknesses in disclosure controls related to segregation of duties and insufficient written policies, which it is addressing while continuing its search for a pharmaceutical-sector target.